Double-blind mealtime faster-acting insulin aspart vs insulin aspart in basal-bolus improves glycaemic control in Type 1 diabetes: the onset 1 trial

被引：0
|
作者：
Russell-Jones, D. [1 ,2 ]
Bode, B. W. [3 ]
De Block, C. [4 ]
Franek, E. [5 ]
Heller, S. [6 ]
Mathieu, C. [7 ]
Philis-Tsimikas, A. [8 ]
Rose, L. [9 ]
Woo, V. [10 ]
Osterskov, A. B. [11 ]
Graungaard, T. [12 ]
Bergenstal, R. [13 ]
机构：
[1] Royal Surrey Cty Hosp, Diabet & Endocrinol, Guildford, Surrey, England
[2] Univ Surrey, Diabet & Endocrinol, Guildford, Surrey, England
[3] Atlanta Diabet Associates, Atlanta, GA USA
[4] Univ Antwerp Hosp, Dept Endocrinol Diabetol & Metab, Antwerp, Belgium
[5] Polish Acad Sci, Mossakowski Clin Res Ctr, Warsaw, Poland
[6] Univ Sheffield, Unit Diabet & Endocrinol, Sheffield, S Yorkshire, England
[7] Univ Hosp Leuven, Lab & Clin Expt Med & Endocrinol, Leuven, Belgium
[8] Scripps Hlth, Scripps Whittier Diabet Inst, San Diego, CA USA
[9] Diabet Res Inst, Munster, Germany
[10] Univ Manitoba, Sect Endocrinol & Metab, Winnipeg, MB, Canada
[11] Global Dev, Insulin & Devices, Soborg, Denmark
[12] Novo Nordisk AS, Biostat Aalborg 2, Aalborg, Denmark
[13] Pk Nicollet, Int Diabet Ctr, Minneapolis, MN USA
来源：
DIABETIC MEDICINE | 2017年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A10
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [1] Double-Blind Mealtime Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Improves Glycemic Control in T1D: The Onset® 1 Trial
    Russell-Jones, David
    Bode, Bruce W.
    De Block, Christophe
    Franek, Edward
    Heller, Simon R.
    Mathieu, Chantal
    Philis-Tsimikas, Athena
    Rose, Ludger
    Woo, Vincent C.
    Osterskov, Anne Birk
    Graungaard, Tina
    Bergenstal, Richard
    [J]. DIABETES, 2016, 65 : A77 - A77
  • [2] Double-blind mealtime faster-acting insulin aspart improves glycaemic control with superior reduction in postprandial glucose excursions vs insulin aspart in type 1 diabetes: onset® 1
    Russell-Jones, D.
    Bode, B. W.
    De Block, C.
    Franek, E.
    Heller, S.
    Mathieu, C.
    Philis-Tsimikas, A.
    Rose, L.
    Woo, V.
    Osterskov, A. B.
    Graungaard, T.
    Bergenstal, R. M.
    [J]. DIABETOLOGIA, 2016, 59 : S6 - S6
  • [3] Faster-acting insulin aspart vs insulin aspart as part of basal-bolus therapy improves postprandial glycaemic control in uncontrolled type 2 diabetes: the onset® 2 trial
    Bowering, K.
    Case, C.
    Harvey, J.
    Reeves, M.
    Sampson, M.
    Strzinek, R.
    Bretler, D. -M.
    Bang, R. B.
    Bode, B. W.
    [J]. DIABETOLOGIA, 2016, 59 : S399 - S400
  • [4] Faster-acting insulin aspart vs insulin aspart as part of basal-bolus therapy improves postprandial glycaemic control in uncontrolled Type 2 diabetes in the double-blinded onset 2 trial
    Saravanan, P.
    Bowering, K.
    Case, C.
    Harvey, J.
    Reeves, M.
    Sampson, M.
    Strzinek, R.
    Bretler, D. M.
    Bang, R. B.
    Bode, B. W.
    [J]. DIABETIC MEDICINE, 2017, 34 : 21 - 21
  • [5] IMPROVED POSTPRANDIAL GLYCAEMIC CONTROL WITH FASTER-ACTING INSULIN ASPART VS INSULIN ASPART IN SUBJECTS WITH TYPE 1 DIABETES USING CSII IN PUMPS
    Bode, B. W.
    Hyveled, L.
    Tamer, S. C.
    Demissie, M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A40 - A40
  • [6] Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial
    Heise, Tim
    Zijlstra, Eric
    Nosek, Leszek
    Rikte, Tord
    Haahr, Hanne
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 208 - 215
  • [7] Faster-Acting Insulin Aspart vs. Insulin Aspart as Part of Basal-Bolus Therapy Improves Postprandial Glycemic Control in Uncontrolled T2D in the Double- Blinded Onset® 2 Trial
    Bowering, Keith
    Case, Christopher
    Harvey, John
    Reeves, Michael
    Sampson, Mike
    Strzinek, Robert
    Bretler, Ditte-Marie
    Bang, Rikke Beck
    Bode, Bruce W.
    [J]. DIABETES, 2016, 65 : A63 - A63
  • [8] Adding faster-acting insulin aspart to basal insulin significantly improved glycaemic control in adults with Type 2 diabetes: the onset 3 trial
    Saravanan, P.
    Rodbard, H.
    Tripathy, D.
    Velazquez, M. V.
    Demissie, M.
    Tamer, S. Can
    Piletic, M.
    [J]. DIABETIC MEDICINE, 2017, 34 : 69 - 69
  • [9] Adding faster-acting insulin aspart to basal insulin significantly improved glycaemic control in adults with type 2 diabetes: the onset® 3 trial
    Piletic, M.
    Tripathy, D.
    Velazquez, M. Vidrio
    Demissie, M.
    Tamer, S. Can
    Rodbard, H.
    [J]. DIABETOLOGIA, 2016, 59 : S400 - S400
  • [10] Copenfast trial: foetal growth and glycaemic control in pregnant women with type 1 or type 2 diabetes randomised to faster-acting insulin aspart or insulin aspart
    Norgaard, S.
    Soholm, J.
    Mathiesen, E.
    Norgaard, K.
    Clausen, T.
    Holmager, P.
    Do, N.
    Damm, P.
    Ringholm, L.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S122 - S122
12345